Apremilast ESTEEM Program Meets Prima...

Apremilast ESTEEM Program Meets Primary and Major Secondary Endpoint...

There are 2 comments on the PR-inside.com story from Jan 7, 2013, titled Apremilast ESTEEM Program Meets Primary and Major Secondary Endpoint.... In it, PR-inside.com reports that:

Celgene International Sarl, a subsidiary of Celgene Corporation , today announced that statistical significance for the primary endpoint of PASI 75 at week 16 was achieved for patients receiving apremilast 30 mg BID monotherapy in both the ESTEEM 1 & 2 phase III studies.

Join the discussion below, or Read more at PR-inside.com.

Since: Sep 12

Location hidden

#1 Jan 7, 2013
As study found that 10 to 30 percent of psoriasis patient develop psoriatic arthritis, but there may some precautions to avoid these as it causes joint pain, joint stiffness and swelling.
kmc2749

Austin, TX

#2 Jan 15, 2013
To learn more about Apremilast, check out http://www.rxwiki.com/apremilast

Tell me when this thread is updated:

Subscribe Now Add to my Tracker

Add your comments below

Characters left: 4000

Please note by submitting this form you acknowledge that you have read the Terms of Service and the comment you are posting is in compliance with such terms. Be polite. Inappropriate posts may be removed by the moderator. Send us your feedback.

Health Discussions

Title Updated Last By Comments
News Republican health care plan unveiled: Cut Medic... 39 min BHM5267 28
News Which GOP senators have concerns with the healt... 1 hr Denizen_Kate 19
News GOP governors don't see 'Obamacare' going away (Oct '14) 1 hr Medicaid is American 217
NEW Dirty Ki...K (Sep '16) 2 hr Anon 22
News Nine questions we have about the Senate health ... 9 hr KillCommies 2
News Flu vaccine ineffective for people 65 and older... 14 hr VACCINES MAIM KILL 1
News CDC panel again advises against FluMist 14 hr VACCINES MAIM KILL 1
Nudity at doctor's office (Mar '07) Wed David 176
More from around the web